LAUSANNE, Switzerland, May 28, 2014 /PRNewswire via COMTEX/ -- LAUSANNE, Switzerland, May 28, 2014 /PRNewswire/ --
Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that new data on the investigational compounds Debio 1143 (SMAC mimetic), Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor), and Debio 0932 (Hsp90 inhibitor) will be presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2014, in Chicago.
Help employers find you! Check out all the jobs and post your resume.
